The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings.


Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
29 04 2022
Historique:
received: 10 03 2022
accepted: 15 03 2022
pubmed: 18 3 2022
medline: 3 5 2022
entrez: 17 3 2022
Statut: epublish

Résumé

The improper expression of glucose-dependent insulinotropic polypeptide receptor (GIPR) and the GIP/GIPR axis activation has been increasingly recognized in endocrine tumors, with a potential diagnostic and prognostic value. A high tumor-to-normal tissue ratio (T/N ratio) of GIPR was reported both in humans' and in rats' medullary thyroid cancer (MTC), suggesting a direct link between the neoplastic transformation and the mechanism of receptor overexpression. In this study, we evaluated the potential diagnostic and prognostic significance of GIPR expression in a large cohort of MTC patients by correlating GIPR mRNA steady-state levels to clinical phenotypes. The molecular effect of GIP/GIPR axis stimulation in MTC-derived cells was also determined. We detected GIPR expression in ~80% of tumor specimens, especially in sporadic, larger, advanced-stage cancers with higher Ki-67 values. GIPR stimulation induced cAMP elevation in MTC-derived cells and a small but significant fluctuation in Ca2+, both likely associated with increased calcitonin secretion. On the contrary, the effects on PI3K-Akt and MAPK-ERK1/2 signaling pathways were marginal. To conclude, our data confirm the high T/N GIPR ratio in MTC tumors and suggest that it may represent an index for the degree of advancement of the malignant process. We have also observed a functional coupling between GIP/GIPR axis and calcitonin secretion in MTC models. However, the molecular mechanisms underlying this process and the possible implication of GIP/GIPR axis activation in MTC diagnosis and prognosis need further evaluation.

Identifiants

pubmed: 35298396
doi: 10.1530/ERC-21-0258
pii: ERC-21-0258
doi:

Substances chimiques

Receptors, Gastrointestinal Hormone 0
Gastric Inhibitory Polypeptide 59392-49-3
Calcitonin 9007-12-9
gastric inhibitory polypeptide receptor D6H00MV7K8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-284

Auteurs

Daniela Regazzo (D)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Loris Bertazza (L)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Eva Galletta (E)

Department of Biology, University of Padova, Padova, Italy.

Susi Barollo (S)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Alberto Mondin (A)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Stefania Zovato (S)

Hereditary Tumors Unit, Veneto Institute of Oncology-IOV-IRCCS, Padova, Italy.

Maurizio Iacobone (M)

Department of Surgery, Oncology and Gastroenterology - Endocrine Surgery Unit, Padova University Hospital, Padova, Italy.

Eleonora Zilio (E)

Department of Biology, University of Padova, Padova, Italy.

Carla Scaroni (C)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Claudia Maria Radu (CM)

Department of Medicine - General Medicine and Thrombotic and Haemorrhagic Diseases Unit, Padova University Hospital, Padova, Italy.

Giulietta di Benedetto (G)

Neuroscience Institute, National Research Council, Padova Section, Padova, Italy.
Foundation for Advanced Biomedical Research, Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Caterina Mian (C)

Department of Medicine - Endocrinology Unit, Padova University Hospital, Padova, Italy.

Konstantinos Lefkimmiatis (K)

Foundation for Advanced Biomedical Research, Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Gianluca Occhi (G)

Department of Biology, University of Padova, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH